Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 13.9% Higher – Time to Buy?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) traded up 13.9% during trading on Tuesday . The stock traded as high as $14.00 and last traded at $14.2320. 48,663 shares traded hands during mid-day trading, a decline of 0% from the average session volume of 48,719 shares. The stock had previously closed at $12.50.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. HC Wainwright boosted their target price on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. JonesTrading assumed coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They issued a “buy” rating and a $15.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Armata Pharmaceuticals has an average rating of “Buy” and an average target price of $15.00.

Armata Pharmaceuticals Trading Down 2.7%

The company has a market cap of $495.60 million, a P/E ratio of -2.81 and a beta of 1.38. The business has a 50 day moving average price of $10.37 and a 200-day moving average price of $7.54.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($3.23). The firm had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.74 million.

Institutional Investors Weigh In On Armata Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Armata Pharmaceuticals in the 4th quarter valued at $108,000. Millennium Management LLC bought a new stake in Armata Pharmaceuticals in the 4th quarter valued at $164,000. OMERS ADMINISTRATION Corp bought a new stake in Armata Pharmaceuticals in the 4th quarter valued at $177,000. SeaCrest Wealth Management LLC raised its stake in Armata Pharmaceuticals by 17.3% in the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after acquiring an additional 6,034 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in Armata Pharmaceuticals in the 4th quarter valued at $284,000. Institutional investors own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.